Across the recent three months, 7 analysts have shared their insights on Azenta (NASDAQ:AZTA), expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 0 | 2 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 3 | 0 | 2 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $70.43, along with a high estimate of $75.00 and a low estimate of $60.00. Experiencing a 2.52% decline, the current average is now lower than the previous average price target of $72.25.
Investigating Analyst Ratings: An Elaborate Study
A comprehensive examination of how financial experts perceive Azenta is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| David Saxon | Needham | Lowers | Buy | $69.00 | $75.00 |
| David Saxon | Needham | Maintains | Buy | $75.00 | $75.00 |
| Vijay Kumar | Evercore ISI Group | Lowers | In-Line | $60.00 | $64.00 |
| Matthew Stanton | Jefferies | Announces | Hold | $64.00 | - |
| David Saxon | Needham | Maintains | Buy | $75.00 | - |
| David Saxon | Needham | Maintains | Buy | $75.00 | $75.00 |
| David Saxon | Needham | Maintains | Buy | $75.00 | - |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Azenta. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Azenta compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Azenta's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Capture valuable insights into Azenta's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Azenta analyst ratings.
All You Need to Know About Azenta
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has two reportable segments that are Life Sciences Products and Life Sciences Services. It generates a substantial part of its revenue from its Life Sciences Services segment.
Azenta: Delving into Financials
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Challenges: Azenta's revenue growth over 3 months faced difficulties. As of 31 December, 2023, the company experienced a decline of approximately -13.48%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Azenta's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -10.19% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Azenta's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -0.63%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -0.55%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.03.
Understanding the Relevance of Analyst Ratings
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.